Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities-Reference-Cited by-同舟云学术

Atopic dermatitis from adolescence to adulthood in the TOACS cohort: prevalence, persistence and comorbidities

Published:2015-04-16 Issue:7 Volume:70 Page:836-845
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Mortz C. G.¹,Andersen K. E.¹,Dellgren C.²,Barington T.²³,Bindslev-Jensen C.¹

Affiliation:

1. Department of Dermatology and Allergy Centre; Odense Research Centre for Anaphylaxis (ORCA); Odense University Hospital; University of Southern Denmark; Odense Denmark

2. Department of Clinical Immunology; Odense University Hospital; University of Southern Denmark; Odense Denmark

3. OPEN (Odense Patient data Exploratory Network); Odense University Hospital; University of Southern Denmark; Odense Denmark

Funder

Aage Bang's Foundation

Odense University Hospital Research Council

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Reference48 articles.

1. Prevalence of atopic dermatitis, asthma, allergic rhinitis, and hand and contact dermatitis in adolescents. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis;Mortz;Br J Dermatol,2001

2. Stable incidence of atopic dermatitis among children in Denmark during the 1990s;Olesen;Acta Derm Venereol,2005

3. Development of atopic dermatitis in the DARC birth cohort;Eller;Pediatr Allergy Immunol,2010

4. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood;Williams;J Allergy Clin Immunol,1999

5. Epidemiology of atopic dermatitis: a review;DaVeiga;Allergy Asthma Proc,2012

Cited by 213 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atopic Dermatitis;Dermatologic Clinics;2024-10

2. Atopic Dermatitis;Dermatologic Clinics;2024-10

3. VINDICATE-P;Dermatologic Clinics;2024-10

4. V Brazilian Consensus on Rhinitis – 2024;Brazilian Journal of Otorhinolaryngology;2024-09

5. Efficacy, Safety, and Early Relapse After Cessation of Upadacitinib Versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China;Dermatitis®;2024-08-20